ABIVAX: Details on share capital and voting rights

On July 17, 2025, ABIVAX released key information on its capital structure. The company, listed on Euronext Paris (ABVX), has a share capital of €634,719.33. As of June 30, 2025, ABIVAX held 63,471,933 shares. The total number of theoretical and exercisable voting rights is 72,784,660. These voting rights include shares without voting rights, in accordance with Article 223-11 of the AMF General Regulation. This data is essential for crossing shareholding thresholds and informing investors.

The Paris-based company develops therapeutic treatments for chronic inflammatory diseases. Their research is primarily focused on the drug candidate obefazimod, currently in phase 3 clinical development.